1. Home
  2. UVE vs ANAB Comparison

UVE vs ANAB Comparison

Compare UVE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVE
  • ANAB
  • Stock Information
  • Founded
  • UVE 1990
  • ANAB 2005
  • Country
  • UVE United States
  • ANAB United States
  • Employees
  • UVE N/A
  • ANAB N/A
  • Industry
  • UVE Property-Casualty Insurers
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • UVE Finance
  • ANAB Health Care
  • Exchange
  • UVE Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • UVE 642.7M
  • ANAB 759.5M
  • IPO Year
  • UVE 1992
  • ANAB 2017
  • Fundamental
  • Price
  • UVE $24.08
  • ANAB $18.40
  • Analyst Decision
  • UVE Buy
  • ANAB Buy
  • Analyst Count
  • UVE 1
  • ANAB 10
  • Target Price
  • UVE $25.00
  • ANAB $36.38
  • AVG Volume (30 Days)
  • UVE 186.6K
  • ANAB 907.9K
  • Earning Date
  • UVE 04-24-2025
  • ANAB 05-08-2025
  • Dividend Yield
  • UVE 3.19%
  • ANAB N/A
  • EPS Growth
  • UVE N/A
  • ANAB N/A
  • EPS
  • UVE 2.01
  • ANAB N/A
  • Revenue
  • UVE $1,520,536,000.00
  • ANAB $91,280,000.00
  • Revenue This Year
  • UVE N/A
  • ANAB N/A
  • Revenue Next Year
  • UVE $3.77
  • ANAB $59.43
  • P/E Ratio
  • UVE $12.00
  • ANAB N/A
  • Revenue Growth
  • UVE 9.27
  • ANAB 432.03
  • 52 Week Low
  • UVE $16.50
  • ANAB $12.21
  • 52 Week High
  • UVE $24.14
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • UVE 74.18
  • ANAB 55.72
  • Support Level
  • UVE $21.23
  • ANAB $17.50
  • Resistance Level
  • UVE $21.95
  • ANAB $19.60
  • Average True Range (ATR)
  • UVE 0.66
  • ANAB 1.34
  • MACD
  • UVE 0.21
  • ANAB 0.16
  • Stochastic Oscillator
  • UVE 98.43
  • ANAB 57.04

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums. It operates within Florida and across the United States. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: